TuHURA Biosciences (HURA) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 26.7% versus a loss of 78.2%. Over five years, NBP leads with a -98.1% price change compared with -99.9% for HURA. NovaBridge Biosciences is the larger company by market cap ($146.2 million vs $112.2 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HURA | NBP |
|---|---|---|
| Share price | $1.76 | $1.26 |
| Market cap | $112.16M | $146.16M |
| 1-day change | -3.83% | -2.33% |
| YTD return | +132.50% | -68.34% |
| 1-year return | -26.67% | -78.16% |
| 5-year return | -99.89% | -98.13% |
| EPS (TTM) | $-0.54 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-30.05M | $-46.27M |
| 52-week high | $3.43 | $5.97 |
| 52-week low | $0.41 | $1.26 |
| Distance from 52-week high | -48.69% | -78.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +356.82% | +614.29% |
| Average volume | 221.74K | 390.05K |
| Shares outstanding | 63.73M | 116.00M |
| Employees | 22 | 30 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed NBP by 51.5 percentage points over the past year.
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
HURA vs NBP FAQ
Which is bigger, TuHURA Biosciences or NovaBridge Biosciences?
NovaBridge Biosciences (NBP) is larger, with a market capitalization of $146.16M compared with $112.16M for TuHURA Biosciences (HURA).
Which stock has performed better over the past year, HURA or NBP?
HURA returned -26.67% over the past 12 months, compared with -78.16% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are TuHURA Biosciences and NovaBridge Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.